Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 197, Issue 3, Pages 302-305Publisher
WILEY
DOI: 10.1111/bjh.18073
Keywords
COVID-19; coronavirus; haematological oncology; vaccine; vaccination; 3rd dose
Categories
Ask authors/readers for more resources
The mRNA COMIRNATY vaccine has been administered to 392 patients with a two-dose regimen, resulting in an overall antibody response of 70%. The initial results of administering a third dose to 80 patients who did not achieve seroconversion or had a weak response show promise, especially for patients on anti-CD38 therapy.
We have vaccinated 392 patients with two doses of mRNA COMIRNATY vaccine with an overall antibody response of 70% (best in cMPN, worst in CLL). We have then vaccinated 80 patients who did not achieve seroconversion or were low responders with a third dose of COMIRNATY vaccine. Our first results show promise, especially for patients on anti-CD38 therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available